Avoid common mistakes on your manuscript.
Erratum to: Rheumatol Ther DOI 10.1007/s40744-017-0061-7
In the original publication, ADA treatment values mentioned in the results section, under the heading ‘Study Outcomes’ were published incorrectly.
The correct text should read “Additionally, compared to PSP users, PSP non-users had significantly lower percentage of patients that started at PAM-13 level 4 at baseline and remained at level 4 until week 78 of ADA treatment (52.4% vs 28.9%, p = 0.001)”.
Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s40744-017-0061-7.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Van den Bosch, F., Ostor, A.J.K., Wassenberg, S. et al. Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study. Rheumatol Ther 4, 97 (2017). https://doi.org/10.1007/s40744-017-0065-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40744-017-0065-3